Why Pfizer Stock Is a Surefire Winner in 2023
Pharmaceutical giant Pfizer (NYSE: PFE) is no stranger to investors; the company is a longtime staple in the healthcare industry. It got a lift in late 2020 and in 2021 as one of the COVID-19 vaccine suppliers, but investors seem to have grown bored with Pfizer's story, and the stock is down about 16% since the start of 2022. The thing is, investors shouldn't be so quick to write off Pfizer stock.